The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients

Transplantation. 1996 Sep 27;62(6):828-30. doi: 10.1097/00007890-199609270-00021.

Abstract

Since thromboembolic complications in transplanted patients are generally attributed to combined abnormalities in platelets and coagulo-lytic system, some hemostatic parameters tPA (tissue plasmogin activator):Ag and activity, its inhibitor-PAIAg and activity, tPA/PAI, thrombin-antithrombin (TAT) and plasmin-antiplasmin complexes (PAP), urokinase-uPA, euglobulin clot lysis time-ECLT, fibrinogen, plasminogen, protein C activity, D-dimer, prothrombin fragments1+2 (F1+2), fibrin monomers, fibronectin, lipoprotein-a, and von Willebrand factor(vWF), were evaluated using commercially available kits. The studies were performed on kidney transplant recipients treated with CsA, azathioprine and prednisone (n=21), and healthy volunteers (n=21). ECLT was significantly prolonged in kidney transplant recipients together with a rise in F1+2,lipoprotein-a, fibrinogen, fibronectin, and vWF when compared with controls. The TPA level was lower, whereas the PAI level was higher in kidney transplant recipients when compared with controls. In conclusion, CsA-treated kidney transplant recipients show evidence of pronounced impairment in fibrinolysis and endothelial damage in comparison with healthy volunteers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Coagulation / drug effects*
  • Blood Coagulation Factors / analysis
  • Cyclosporine / adverse effects
  • Cyclosporine / pharmacology*
  • Cyclosporine / therapeutic use
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / physiology
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis
  • Fibrinogen / analysis
  • Fibrinolysis / drug effects*
  • Fibronectins / analysis
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / pharmacology*
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation*
  • Male
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / analysis
  • Prednisolone / therapeutic use
  • Thromboembolism / blood
  • Thromboembolism / chemically induced
  • Tissue Plasminogen Activator / analysis
  • Urokinase-Type Plasminogen Activator / analysis
  • Zidovudine / therapeutic use

Substances

  • Blood Coagulation Factors
  • Fibrin Fibrinogen Degradation Products
  • Fibronectins
  • Immunosuppressive Agents
  • Plasminogen Activator Inhibitor 1
  • Zidovudine
  • Cyclosporine
  • Fibrinogen
  • Prednisolone
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator